Browse diseases

…r associated risk of CV events among those testing positive for COVID-19.…

… (IQR 84–1184) and median LV ejection fraction 56% (IQR 48–60). MINOCA terminology was documented in medical records for 37/97 patient…

…Introduction Cardiac manifestations in Systemic Sclerosis are common, majority remain subclinical. Significant involvemen…

…%). Interestingly, a majority of respondents would likely treat lcSSc in the presence of subclinical organ involvement, including sub…

…mission rate of 70.8%, with notable activity in myocarditis and inflammatory arthritis. Although JAK inhibition has historically raised concern due to…

… survivors of cardiac arrest. Emerging data on master athletes, atrial fibrillation, coronary calcification and myocardial fibrosis are highlighted…

…ces (n=155).Conclusions Troponin elevation, exemplified here by COVID-19, could reflect systemic vascular injury. Recognising this mecha…

…%) in peripartum cardiomyopathy, 2% (2/102; 95% CI 0% to 7%) in Takotsubo syndrome and 1% (8/594; 95% CI 1% to 3%) for congenital/inherited or gen…

…ed features consistent with immune checkpoint inhibitor–related myasthenia gravis, myocarditis and myositis (triple M syndrome). The patient resp…

…ns and longitudinal outcomes/disease manifestations in incident dermatomyositis cohorts. This study highlights a high burden of glucocorticoid …

…Pertussis is a highly pathogenic respiratory infection that poses a parti…

…tors (ICI) demonstrate significant efficacy in the treatment of cancer but are commonly associated with immune related adverse events.…